{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T05:49:59Z","timestamp":1778392199984,"version":"3.51.4"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Baricitinib is a Janus kinase (JAK) inhibitor that selectively blocks against JAK1 and JAK2 signaling. This study aimed to determine the effect of baricitinib on disease activity based on musculoskeletal ultrasound in patients with rheumatoid arthritis (RA).<\/jats:p>\n            <jats:p>A total of 20 patients with RA receiving baricitinib for 24\u200aweeks were assessed. Ultrasound scores of gray scale and power Doppler synovitis, joint effusion, and bone erosion in each patient were assessed between baseline and 24\u200aweeks for 27 affected joints. Disease activity in RA was evaluated using the disease activity score for 28-joint count with erythrocyte sediment rate (DAS28-ESR), simplified disease activity index (SDAI), and clinical disease activity index (CDAI).<\/jats:p>\n            <jats:p>Treatment with baricitinib for 12\u200aweeks and 24\u200aweeks significantly decreased disease activity composites such as DAS28-ESR, SDAI, and CDAI (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001 for all). Treatment with baricitinib for 24\u200aweeks improved ultrasound-detected gray-scale and power Doppler synovitis and joint effusion compared to baseline (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.002, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.030, and <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.002, respectively). Bone erosion scores were not different between baseline and 24\u200aweeks (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.317). There were no differences in ultrasound abnormalities for improvement based on DAS28-ESR. Changes in power Doppler score were significantly associated with changes in DAS28-ESR (\u03b2\u200a=\u200a0.590, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.044), but not SDAI and CDAI.<\/jats:p>\n            <jats:p>This study demonstrates that baricitinib treatment has a favorable effect on ultrasound-detected abnormalities including synovitis and bone erosion in patients with RA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026739","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T15:58:13Z","timestamp":1629129493000},"page":"e26739","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["The beneficial effect of baricitinib on ultrasound-detected synovial inflammation and bone damage in rheumatoid arthritis"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-0167","authenticated-orcid":false,"given":"Seong-Kyu","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ui Hong","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Yoon","family":"Choe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,7,30]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/acr.24042","article-title":"2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures","volume":"71","author":"England","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s11547-019-01002-2","article-title":"Ultrasound imaging in rheumatoid arthritis","volume":"124","author":"Filippucci","year":"2019","journal-title":"Radiol Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/acr.23551","article-title":"Ultrasonographic efficacy of biologic and targeted synthetic disease-modifying antirheumatic drug therapy in rheumatoid arthritis from a multicenter rheumatoid arthritis ultrasound prospective cohort in Japan","volume":"70","author":"Nishino","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/14397595.2016.1221874","article-title":"Ultrasound disease activity of bilateral wrist and finger joints at three months reflects the clinical response at six months of patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs","volume":"27","author":"Umeda","year":"2017","journal-title":"Mod Rheumatol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13075-017-1320-2","article-title":"Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled","volume":"19","author":"Kawashiri","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/jcph.354","article-title":"The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers","volume":"54","author":"Shi","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s10067-018-4221-0","article-title":"Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study","volume":"37","author":"van der Heijde","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"e000662","DOI":"10.1136\/rmdopen-2018-000662","article-title":"Effects of baricitinib on radiographic progression of structural joint damage at 1\u200ayear in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs","volume":"4","author":"van der Heijde","year":"2018","journal-title":"RMD Open"},{"issue":"(Suppl 2)","key":"R14-20250504","first-page":"375","article-title":"Ultrasound evaluation for monitoring response to baricitinib in rheumatoid arthritis patients at early stage after treatment","volume":"78","author":"Torikai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/art.10877","article-title":"Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis","volume":"48","author":"Szkudlarek","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R17-20250504","first-page":"e23930","article-title":"JAK-STAT and bone metabolism","volume":"2","author":"Li","year":"2013","journal-title":"JAKSTAT"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/cei.12190","article-title":"Inhibition of Janus kinase\/signal transducer and activator of transcription (JAK\/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds","volume":"174","author":"Migita","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1136\/ard.2005.050385","article-title":"Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment","volume":"65","author":"Walker","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R20-20250504","first-page":"2120","article-title":"FDA approves tofacitinib for rheumatoid arthritis","volume":"69","author":"Traynor","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/rheumatology\/kex258","article-title":"Effects of tofacitinib in early arthritis-induced bone loss in an adjuvant-induced arthritis rat model","volume":"57","author":"Vidal","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"02","DOI":"10.1186\/s12950-019-0206-2","article-title":"Inhibition of pSTAT1 by tofacitinib accounts for the early improvement of experimental chronic synovitis","volume":"16","author":"P\u00e9rez-Baos","year":"2019","journal-title":"J Inflamm (Lond)"},{"issue":"(Suppl 2)","key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2018-eular.5054","article-title":"Clinical and musculoskeletal ultrasound assessment of therapeutic response to tofacitinib in patients with rheumatoid arthritis: real-world clinical experience from a single centre in Hong Kong","volume":"77","author":"Yu","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 2)","key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1136\/annrheumdis-2019-eular.4617","article-title":"The JAK inhibitor (baricitinib) inhibits IFNg-induced gliostatin expression in human fibroblast-like synoviocytes","volume":"78","author":"Joyo","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3389\/fimmu.2019.00541","article-title":"Targeting activated synovial fibroblasts in rheumatoid arthritis by peficitinib","volume":"10","author":"Diller","year":"2019","journal-title":"Front Immunol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"325909","DOI":"10.1155\/2015\/325909","article-title":"The role of power Doppler ultrasonography as disease activity marker in rheumatoid arthritis","volume":"2015","author":"Bhasin","year":"2015","journal-title":"Dis Markers"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"07","DOI":"10.1016\/j.ejr.2018.02.001","article-title":"Power Doppler ultrasound in the evaluation of hand joints in rheumatoidarthritis patients in clinical remission: association with composite indexscores and functional status","volume":"41","author":"El-Serougy","year":"2019","journal-title":"Egyptian Rheumatol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s10067-014-2634-y","article-title":"Presence of power Doppler synovitis in rheumatoid arthritis patients with synthetic and\/or biological disease-modifying anti-rheumatic drug-induced clinical remission: experience from a Chinese cohort","volume":"33","author":"Geng","year":"2014","journal-title":"Clin Rheumatol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.277.5332.1630","article-title":"STATs and gene regulation","volume":"277","author":"Darnell","year":"1997","journal-title":"Science"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/intimm\/dxr077","article-title":"IL-1\u03b2 and TNF\u03b1-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis","volume":"23","author":"Mori","year":"2011","journal-title":"Int Immunol"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1002\/art.34649","article-title":"JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production","volume":"64","author":"LaBranche","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"e0181126","DOI":"10.1371\/journal.pone.0181126","article-title":"A Jak1\/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro","volume":"12","author":"Murakami","year":"2017","journal-title":"PLoS One"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:32:24Z","timestamp":1746336744000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026739"}},"subtitle":["Preliminarily data from single center-based observational study for 24 weeks"],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":32,"journal-issue":{"issue":"30","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026739","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,30]]},"assertion":[{"value":"2021-03-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}